Breaking News

Sosei, FUJIFILM Pharma Sign Distribution Pact

By Kristin Brooks | February 4, 2014

Sosei to manufacture and supply antifungal agent

Sosei Group’s Japanese subsidiary, Sosei Co., Ltd., has signed a distribution agreement with FUJIFILM Pharma Co., Ltd for the commercialization of SO-1105 in Japan. SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. The drug is currently registered in 24 European countries, in South Korea, and in the U.S., under the trade names Loramyc/Oravig. Sosei acquired exclusive development and commercialization rights to SO-1105 in Japan from BioAlliance Pharma in May 2011.
 
Sosei will be responsible for registration, manufacturing and supply, and FUJIFILM will be responsible for marketing and distribution of SO-1105. Sosei is eligible to receive a total of 900 million yen as an initial payment and development and regulatory milestones, as well as royalties on sales.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks